|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
NLM365792144 |
003 |
DE-627 |
005 |
20240304232121.0 |
007 |
cr uuu---uuuuu |
008 |
231226s2024 xx |||||o 00| ||eng c |
024 |
7 |
|
|a 10.1002/jcc.27280
|2 doi
|
028 |
5 |
2 |
|a pubmed24n1316.xml
|
035 |
|
|
|a (DE-627)NLM365792144
|
035 |
|
|
|a (NLM)38088485
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Dabbish, Eslam
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Insights on cyclophosphamide metabolism and anticancer mechanism of action
|b A computational study
|
264 |
|
1 |
|c 2024
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a Date Completed 04.03.2024
|
500 |
|
|
|a Date Revised 04.03.2024
|
500 |
|
|
|a published: Print-Electronic
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a © 2023 The Authors. Journal of Computational Chemistry published by Wiley Periodicals LLC.
|
520 |
|
|
|a The oxazaphosphorine cyclophosphamide (CP) is a DNA-alkylating agent commonly used in cancer chemotherapy. This anticancer agent is administered as a prodrug activated by a liver cytochrome P450-catalyzed 4-hydroxylation reaction that yields the active, cytotoxic metabolite. The primary metabolite, 4-hydroxycyclophosphamide, equilibrates with the ring-open aldophosphamide that undergoes β-elimination to yield the therapeutically active DNA cross-linking phosphoramide mustard and the byproduct acrolein. The present paper presents a DFT investigation of the different metabolic phases and an insight into the mechanism by which CP exerts its cytotoxic action. A detailed computational analysis of the energy profiles describing all the involved transformations and the mechanism of DNA alkylation is given with the aim to contribute to an increase of knowledge that, after more than 60 years of unsuccessful attempts, can lead to the design and development of a new generation of oxazaphosphorines
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a DFT
|
650 |
|
4 |
|a DNA
|
650 |
|
4 |
|a alkylating agents
|
650 |
|
4 |
|a cyclophosphamide
|
650 |
|
7 |
|a Cyclophosphamide
|2 NLM
|
650 |
|
7 |
|a 8N3DW7272P
|2 NLM
|
650 |
|
7 |
|a Acrolein
|2 NLM
|
650 |
|
7 |
|a 7864XYD3JJ
|2 NLM
|
650 |
|
7 |
|a DNA
|2 NLM
|
650 |
|
7 |
|a 9007-49-2
|2 NLM
|
700 |
1 |
|
|a Scoditti, Stefano
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Shehata, Mohammed N I
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Ritacco, Ida
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Ibrahim, Mahmoud A A
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Shoeib, Tamer
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Sicilia, Emilia
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Journal of computational chemistry
|d 1984
|g 45(2024), 10 vom: 15. März, Seite 663-670
|w (DE-627)NLM098138448
|x 1096-987X
|7 nnns
|
773 |
1 |
8 |
|g volume:45
|g year:2024
|g number:10
|g day:15
|g month:03
|g pages:663-670
|
856 |
4 |
0 |
|u http://dx.doi.org/10.1002/jcc.27280
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 45
|j 2024
|e 10
|b 15
|c 03
|h 663-670
|